Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 28;13:1640. doi: 10.1038/s41467-022-29336-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Kaplan-Meier estimate of EFS of Chinese pediatric AML patients diagnosed and treated at SCMC. A total of 288 cases with sufficient follow-up information were included in this analysis. Patients were grouped by the fusions, including CBFB-MYH11, 11 cases; RUNX1-RUNX1T1, 78; KMT2A rearranged (MLLr), 45; CBFA2T3-GLIS2, 12; NUP98-KMD5A, 7; NUP98-NSD1, 5; FUS-ERG, 5; other fusions, 33 and fusion negative, 92 (log-rank test, P = 4.963E − 05). b RUNX1-RUNX1T1-positive patients who reached complete remission after the 1^st cycle of induction therapy, and had both CSF3R and KIT-E17 mutations (5 cases), showed inferior prognosis compared to patients carrying only CSF3R (n = 5) or KIT-E17 mutation (n = 17) or none of these two mutations (n = 26) (log-rank test).